Prospective look at liver metastases imaging and tissue patterns in colorectal and breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This non-interventional study collects imaging data and tissue samples from patients with liver metastases from colorectal or breast cancer who are having liver metastases surgically removed. Researchers compare the histopathological growth patterns, particularly desmoplastic versus other patterns, with imaging characteristics to see if imaging can reflect underlying biology. An optional biobanking activity may collect remnant tissue for further study, using tissue that would otherwise be discarded. The goal is to improve understanding of how imaging relates to tumor behavior and to potentially inform future patient care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. ≥ 18 years old.
2. Patients with liver metastatic colorectal or breast carcinoma undergoing a surgical excision of the liver metastases
3. Therapy-naive patients as well as patients with neo-adjuvant therapy are eligible for inclusion
4. Willingness of the patient to participate in this study demonstrated by signed written informed consent

Exclusion Criteria:

1. Patients without MRI or CT of the liver prior to surgery
2. Time interval between medical imaging, CT and/or MRI is more than 12 weeks (nb: time interval is preferably less than 4 weeks but this is not an exclusion criterium)
3. Prior radiofrequency ablation (RFA) or transarterial chemoembolization (TACE) on the liver metastasis that would be operated

Where it's running

• GZA St Augustinus
  Wilrijk, Antwerp, Belgium Recruiting

Study contacts

• Study coordinator: Peter Vermeulen, MD, PhD
• Email: peter.vermeulen@zas.be
• Phone: 0032493194745

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment

  This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07816263

• First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors

  This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.

  Recruiting at 3 sites Phase 1 Sutro Biopharma, Inc. · Orlando, Florida and 5 other locations · NCT07807345

• Oral, Fecal and Tumor Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line Immunotherapy

  This study tests how the oral, gut, and tumor microbiomes relate to response to first-line immunotherapy in Colombian adults with advanced solid cancers.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07676461

• Precision navigation to boost cancer screening participation in high-risk communities

  This study tests whether a personalized navigation program helps adults aged 45–74 in Chinese communities who are at high risk for several cancers to complete recommended free cancer screenings.

  Recruiting at 3 sites Hunan Cancer Hospital · Huaihua, Hunan and 2 other locations · NCT07676383

• Targeted radiopharmaceuticals for GRPR-positive cancers in adults

  A phase 1 study tests two targeted radiopharmaceuticals, radiolabeled Lu-177 and Ac-225 compounds, to treat GRPR-expressing breast, prostate, colorectal, and other solid tumors in adults who have not benefited from standard therapies.

  Recruiting Phase 1 Alpha-9 Oncology USA Inc. · Melbourne N., Victoria and 1 other locations · NCT07661641

• IM-1617 in people with advanced solid cancers

  A first-in-human study will test IM-1617 to see if it is safe and helps treat solid tumors that have spread or cannot be removed.

  Recruiting at 5 sites Phase 1 Immunome, Inc. · New Haven, Connecticut and 4 other locations · NCT07578571

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.